The Efficacy of AGS-003 in mRCC

March 13, 2014
Robert Figlin, MD, FACP

Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma

Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma (mRCC).

Clinical Pearls:

  • In the trial, patients with mRCC received AGS-003 combined with sunitinib
  • Updated results show impressive survival findings, including a doubling in progression-free survival and an improvement in overall survival, for patients in the trial compared with a cohort of similar patients that were matched from other trials
  • In the ongoing phase III ADAPT trial, AGS-003 should be able to demonstrate that a personalized vaccine in combination with sunitinib can enhance outcomes for patients with newly diagnosed mRCC